Is Innate Pharma SA halal to invest in?

According to Musaffa's Shariah screening methodology, Innate Pharma SA (IPH.PA) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Innate Pharma SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Innate Pharma SA using these criteria to determine its compliance status.

Can Muslims buy shares of Innate Pharma SA?

Muslim investors may consider investing in Innate Pharma SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Innate Pharma SA classified as NOT HALAL?

Musaffa determines the Shariah status of Innate Pharma SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Innate Pharma SA updated?

The Shariah compliance status of Innate Pharma SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Innate Pharma SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Innate Pharma SA?

You can check the latest Shariah compliance status of Innate Pharma SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Innate Pharma SA IPH.PA

€1.93 €0.04 (2.01%) 1D

Last Updated: May 15, 12:00 AM·XPAR

IPH.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 20, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Innate Pharma SA (IPH.PA)

Based on 8 analysts giving stock ratings to Innate Pharma SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Innate Pharma SA. Stock Analysis IPH.PA

France Health Care Micro Cap Report: 2025 Annual

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company employs 164 full-time employees The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.

Key Statistics of Innate Pharma SA (IPH.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€1.73€2.21

Today's Open

€1.97

Volume

180.59K

P/E Ratio (TTM)

52 Week Range

€1.03€2.20

Market Cap

117.00M

Avg. Volume

103.36K

Dividend Yield

Financial Metrics & Statements of Innate Pharma SA (IPH.PA)

FAQ's for Innate Pharma SA (IPH.PA)

According to Musaffa’s Shariah screening methodology, Innate Pharma SA (IPH.PA) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.